Sipuleucel ‐T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database

ConclusionsPatients with CV risk factors who are receiving sipuleucel ‐T may be at higher risk for congestive heart failure, myocardial ischemia, and supraventricular tachycardia. Electrocardiograms during weekly sipuleucel‐T infusions and left ventricular function monitoring with echocardiogram should be considered in these patients. Our findings are suggestive o f another rare presentation of T‐cell‐mediated CV toxicity with cancer immunotherapy.

Source: ESC Heart Failure - May 3, 2021 Category: Cardiology Authors: Melissa Y.Y. Moey, Rahim A. Jiwani, Kotaro Takeda, Karyn Prenshaw, R. Wayne Kreeger, John Inzerillo, Darla K. Liles, C. Bogdan Marcu, B énédicte Lebrun‐Vignes, D. Lynn Morris, Sivakumar Ardhanari, Joe‐Elie Salem Tags: Short Communication Source Type: research